236 related articles for article (PubMed ID: 7705868)
1. Anti tubercular treatment induced hepatotoxicity: does acetylator status matter?
Singh J; Garg PK; Thakur VS; Tandon RK
Indian J Physiol Pharmacol; 1995 Jan; 39(1):43-6. PubMed ID: 7705868
[TBL] [Abstract][Full Text] [Related]
2. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.
Jasmer RM; Saukkonen JJ; Blumberg HM; Daley CL; Bernardo J; Vittinghoff E; King MD; Kawamura LM; Hopewell PC;
Ann Intern Med; 2002 Oct; 137(8):640-7. PubMed ID: 12379063
[TBL] [Abstract][Full Text] [Related]
3. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
4. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
Chang KC; Leung CC
Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
[No Abstract] [Full Text] [Related]
5. Predisposing factors in hepatitis induced by isoniazid-rifampin treatment of tuberculosis.
Grönhagen-Riska C; Hellstrom PE; Fröseth B
Am Rev Respir Dis; 1978 Sep; 118(3):461-6. PubMed ID: 707874
[TBL] [Abstract][Full Text] [Related]
6. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity.
Sharma SK; Singla R; Sarda P; Mohan A; Makharia G; Jayaswal A; Sreenivas V; Singh S
Clin Infect Dis; 2010 Mar; 50(6):833-9. PubMed ID: 20156055
[TBL] [Abstract][Full Text] [Related]
7. Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is.
Ann Intern Med; 2002 Oct; 137(8):I32. PubMed ID: 12379094
[No Abstract] [Full Text] [Related]
8. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.
Tostmann A; Boeree MJ; Aarnoutse RE; de Lange WC; van der Ven AJ; Dekhuijzen R
J Gastroenterol Hepatol; 2008 Feb; 23(2):192-202. PubMed ID: 17995946
[TBL] [Abstract][Full Text] [Related]
9. Effects of two pulmonary tuberculosis drug treatments and acetylator status on liver function in a Zimbabwean population.
Neill P; Pringle D; Mhonda M; Kusema T; Nhachi CF
Cent Afr J Med; 1990 Apr; 36(4):104-7. PubMed ID: 2225025
[TBL] [Abstract][Full Text] [Related]
10. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
[TBL] [Abstract][Full Text] [Related]
11. NAT2 slow acetylator associated with anti-tuberculosis drug-induced liver injury in Thai patients.
Wattanapokayakit S; Mushiroda T; Yanai H; Wichukchinda N; Chuchottawon C; Nedsuwan S; Rojanawiwat A; Denjanta S; Kantima T; Wongyai J; Suwankesawong W; Rungapiromnan W; Kidkeukarun R; Bamrungram W; Chaiwong A; Suvichapanich S; Mahasirimongkol S; Tokunaga K
Int J Tuberc Lung Dis; 2016 Oct; 20(10):1364-1369. PubMed ID: 27725049
[TBL] [Abstract][Full Text] [Related]
12. Drug-induced hepatotoxicity of anti-tuberculosis drugs and their serum levels.
Jeong I; Park JS; Cho YJ; Yoon HI; Song J; Lee CT; Lee JH
J Korean Med Sci; 2015 Feb; 30(2):167-72. PubMed ID: 25653488
[TBL] [Abstract][Full Text] [Related]
13. Hepatotoxicity after a short course of low-dose pyrazinamide.
al Sarraf KA; Michielsen PP; Hauben EI; Lefebure A; Ramon AM; Van Marck EA; Pelckmans PA
Acta Gastroenterol Belg; 1996; 59(4):251-3. PubMed ID: 9085628
[TBL] [Abstract][Full Text] [Related]
14. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for antituberculous chemotherapy-induced hepatotoxicity in Japanese pediatric patients.
Ohkawa K; Hashiguchi M; Ohno K; Kiuchi C; Takahashi S; Kondo S; Echizen H; Ogata H
Clin Pharmacol Ther; 2002 Aug; 72(2):220-6. PubMed ID: 12189369
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of N-acetylcysteine on antituberculosis drug-induced hepatotoxicity.
Baniasadi S; Eftekhari P; Tabarsi P; Fahimi F; Raoufy MR; Masjedi MR; Velayati AA
Eur J Gastroenterol Hepatol; 2010 Oct; 22(10):1235-8. PubMed ID: 20461008
[TBL] [Abstract][Full Text] [Related]
17. First line anti-tuberculosis induced hepatotoxicity: incidence and risk factors.
Bouazzi OE; Hammi S; Bourkadi JE; Tebaa A; Tanani DS; Soulaymani-Bencheikh R; Badrane N; Bengueddour R
Pan Afr Med J; 2016; 25():167. PubMed ID: 28292129
[TBL] [Abstract][Full Text] [Related]
18. Hepatotoxicity due to rifampicin, isoniazid and pyrazinamide in patients with tuberculosis: is anti-HCV a risk factor?
Nader LA; de Mattos AA; Picon PD; Bassanesi SL; De Mattos AZ; Pineiro Rodriguez M
Ann Hepatol; 2010; 9(1):70-4. PubMed ID: 20308724
[TBL] [Abstract][Full Text] [Related]
19. Management of and risk factors related to hepatotoxicity during tuberculosis treatment.
Babalık A; Arda H; Bakırcı N; Ağca S; Oruç K; Kızıltaş S; Cetintaş G; Calışır HC
Tuberk Toraks; 2012; 60(2):136-44. PubMed ID: 22779934
[TBL] [Abstract][Full Text] [Related]
20. Antituberculosis drugs and hepatotoxicity.
Yew WW; Leung CC
Respirology; 2006 Nov; 11(6):699-707. PubMed ID: 17052297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]